The presentation of the 12-month results from the Lutonix Global Real-World Registry at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting has been announced by C. R. Bard, just months after publication of the 1-year data from the Lutonix 035 Drug Coated Balloon (DCB) Catheter pivotal, randomised Levant 2 trial in the New England Journal of Medicine.
Silk Road Medical has announced the receipt of up to US$57 million investment in the form of equity and debt funding from new and existing investors. CRG joins Warburg Pincus and The Vertical Group as an equity investor, and has led the debt financing.
Bolton Medical has announced the first commercial implant of the Treo abdominal stent graft system. Theodosios Bisdas and Giovanni Torsello (St Franciscus Hospital Muenster in Munster, Germany) performed this first procedure, the company reported.
The IN.PACT Admiral drug-coated balloon (DCB) provides superior clinical outcomes at two years compared to standard balloon angioplasty for the interventional treatment of peripheral arterial disease in the superficial femoral arteries and/or popliteal arteries.
The first two cases in the EffPac randomised clinical multicentre trial of its luminor 35 drug-eluting balloon system have been successfully performed, according to iVascular.
Riccardo Lencioni joined Sylvester Comprehensive Cancer Center, Miami, USA, as director of Interventional Oncology Research from the University of Pisa in Italy, where he was a professor at the School of Medicine. Lencioni is an accomplished interventional oncologist, particularly well-known for his influential work on liver cancer.
BTG and Mirada, a medical imaging software company, have announced an important collaboration to develop dosimetry software solutions to optimise radioembolization therapy with TheraSphere.
The as-yet unpublished, five-year outcome after catheter-directed thrombolysis for upper femoral and/or iliac vein thrombosis, as determined from the randomised, controlled trial, the CaVenT study, were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting (26–30 September, Lisbon, Portugal).
Jim Reekers, Amsterdam, The Netherlands, delivering the Josef Roesch honorary lecture at CIRSE 2015 (26–30 September, Lisbon, Portugal), urged delegates to look at new definitions for critical limb ischaemia and pointed to the potential of perfusion angiography in predicting the outcome of endovascular intervention. “Look past the re-opening of vessels alone,” he said.
Gilles Soulez, Montréal, Canada, delivered the Andreas Gruentzig lecture at the Cardiovascular and Interventional Radiological Society of Europe’s annual meeting (26–30 September, Lisbon, Portugal). “We need to change the way we look at abdominal aortic aneurysms,” he urged.
Galil Medical has announced the launch of its latest product offerings, the Icepearl 2.1 CX and Iceforce 2.1 CX cryoablation needles. A press release from the company states that the patented needle design characteristics of these new needles offer the largest iceball via the narrowest needle shaft diameter on the market today.
Medtronic has announced a preview of notable clinical studies that will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium (11–15 October, San Francisco, USA). The two-year results from the pivotal IN.PACT SFA clinical trial will be unveiled in a First Report Investigation presentation and data for the company’s CoreValve transcathter aortic valve implantation (TAVI) device will also be presented.
The first US commercial case using Silk Road Medical’s Enroute transcarotid stent system has been successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, Hawaii, by vascular surgeon Peter A Schneider. The Enroute transcarotid stent is designed specifically for transcarotid artery revascularisation (TCAR), combining the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
Terumo and Quirem Medical, a commercial stage Dutch medical technology company that focuses on radioembolization, have announced that Terumo has made an equity investment in Quirem Medical.
BTG announced on 6 August 2015 that Health Canada has issued a notice of compliance approving polidocanol injectable foam (Varithena, BTG) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, above and below the knee.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos